| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000008322 |
| Receipt No. | R000009800 |
| Scientific Title | Feasibility Study of Unified Protocol for Anxiety and Depressive Disorders |
| Date of disclosure of the study information | 2012/07/12 |
| Last modified on | 2022/01/11 (Ver. 8) |
| Basic information | ||
| Public title | Feasibility Study of Unified Protocol for Anxiety and Depressive Disorders | |
| Acronym | Open label study of Unified Protocol for Emotional Disorders | |
| Scientific Title | Feasibility Study of Unified Protocol for Anxiety and Depressive Disorders | |
| Scientific Title:Acronym | Open label study of Unified Protocol for Emotional Disorders | |
| Region |
|
|
| Condition | ||
| Condition | Anxiety Disorders, Depressive Disorders | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To examine the feasibility of Unified Protocol for anxiety and depressive disorders in Japanese setting |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | Severity of anxiety symptoms assessed by the SIGH-A (0 week vs 1 week after the completion of intervention) |
| Key secondary outcomes | 1. Diagnoses assessed by the M.I.N.I.
2. Objective severity of depressive symptoms (GRID-HAM-D) 3. Subjective severity of depressive symptoms (BDI-II) 4. Quality of Life (EuroQol etc) 5. Subjective symptoms for primary diagnosis (self-report scale) 6. Emotion Regulation (ERQ) 7. Experienced Emotion (PANAS) 8. Drop Out rates 9. Adverse Events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | CBT (Unified Protocol) | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Subjects with current DSM-IV Panic disorder with/without Agoraphobia, Agoraphobia without history of Panic Disorder, Specific Phobia, Social Phobia (Social Anxiety Disorder), Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder Not Otherwise Specified, Major Depressive Disorder, Depressive Disorder Not Otherwise Specified
2. HAM-D Anxiety Factor >= 7 3. Age 20 years or older, and 65 years or younger at screening. 4. Subjects who give full consent in the participation of the study |
|||
| Key exclusion criteria | 1. No alcohol or substance use disorder in 6 months prior to the screening.
2. No history or concurrent manic or psychotic episode. 3. No other primary DSM-IV Axis I Disorders in six months prior to the screening. 4. No comorbid of antisocial personality disorder. 5. No serious suicidal ideation at screening. 6. Evidence of unable to participate half or more of the intervention phase. 7. No past treatment of CBT. 8. No structured psychotherapy (except supportive therapy) during the intervention. 9. No major cognitive deficits at screening. 10. No life-threatening, severe or unstable physical disorders at screening. 11. Other relevant reason decided by the investigators. |
|||
| Target sample size | 15 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Center of Neurology and Psychiatry | ||||||
| Division name | National Center for Cognitive Behavior Therapy and Research, Department of Clinical Training | ||||||
| Zip code | |||||||
| Address | Ogawahigashi 4-1-1, Kodaira-shi, Tokyo, Japan | ||||||
| TEL | 042-341-2712(3605) | ||||||
| masayait@ncnp.go.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | National Center of Neurology and Psychiatry | ||||||
| Division name | National Center for Cognitive Behavior Therapy and Research | ||||||
| Zip code | |||||||
| Address | Ogawahigashi 4-1-1, Kodaira-shi, Tokyo, Japan | ||||||
| TEL | 042-341-2712(3605) | ||||||
| Homepage URL | |||||||
| norikokato@ncnp.go.jp | |||||||
| Sponsor | |
| Institute | National Center of Neurology and Psychiatry, National Center for Cognitive Behavior Therapy and Research |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Intramural Research Grant (24-4) for Neurological and Psychiatric Disorders of NCNP |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | National Disaster Medical Center |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立精神・神経医療研究センター(東京都)
国立病院機構 災害医療センター(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | not available |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://doi.org/10.1016/j.beth.2016.02.005 | ||||||
| Number of participants that the trial has enrolled | 17 | ||||||
| Results | The severity of anxiety symptoms decreased significantly after the intervention and remained low for 3 months. | ||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results |
|
||||||
| Baseline Characteristics | 10 female (59%)
Mean age=35.18(SD=10.8) |
||||||
| Participant flow | Referred for study, baseline assessment, enrolled, intervention, post-assessment, 3-month follow-up assessment. | ||||||
| Adverse events | No severe adverse event occurred. | ||||||
| Outcome measures | Structured Interview Guide for the Hamilton Anxiety Rating Scale | ||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009800 |